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summarizes the criteria for when to start ART in HIV-infected children; a review of supporting evidence for these recommendations has been published [2] . The CHER study [3] provides evidence for treating all children less than 12 months of age (infants), and therefore for this age group, the recommendation was categorized as strong with moderate quality of evidence. But for children aged 1 to less than 5 years, evidence to support this recommendation is lacking. The recommendation to treat all children less than 5 years of age regardless of WHO clinical stage or CD4 þ T-cell count was largely driven by programmatic reasons: to scale up paediatric ART in light of low coverage compared with adult ART, to simplify treatment especially with limited access to CD4 þ T-cell count tests and to improve retention, as many programmes were reporting poor follow up of children on pre-ART care. It remains to be seen whether indeed this recommendation will indeed increase paediatric ART uptake and retention.
The evidence informing the choice of initial ART regimens for children under age 3 years and children at least age 3 years (including adolescents) has been summarized in systematic reviews [4, 5] . The WHO recommendations for first-line ART in children and adolescents are summarized in Table 2 .
In general, WHO recommends that all children under age 3 years receive a lopinavir/r-based ART regimen; nevirapine-based ART is recommended only if use of lopinavir/r is not feasible. The preferred dual nucleoside reverse transcriptase inhibitor (NRTI) backbone in firstline ART for children under age 3 years is abacavir or zidovudine in combination with lamivudine; tenofovir disoproxil fumarate is a recommended NRTI option for children age 3 to less than 10 years and is the preferred NRTI for adolescents (ages 10-19 years). When secondline therapy is required because of first-line treatment failure, children who were receiving an NNRTI-based initial ART regimen should switch nevirapine to lopinavir/r, continue lamivudine and switch their other NRTI (abacavir or tenofovir disoproxil fumarate to zidovudine, zidovudine to abacavir, or, if 2 years old, zidovudine to tenofovir disoproxil fumarate). Children at least 3 years old who are failing a lopinavir/r-based initial ART regimen should receive efavirenz in place of lopinavir/r, continue lamivudine and switch their other NRTI (abacavir or tenofovir disoproxil fumarate to zidovudine, zidovudine to tenofovir disoproxil fumarate or abacavir). For children less than 3 years old failing a lopinavir/r-based initial ART regimen, no change in regimen is recommended unless there is advanced clinical disease progression or lack of adherence specifically because of poor palatability of lopinavir/r; in such cases, an nevirapine-based ART regimen should be considered.
The WHO recommendations emphasize the choice of lopinavir/r over nevirapine in first-line therapy for children less than 3 years old, based on randomized clinical trials that demonstrated superior efficacy of lopinavir/r, both for infants with and without prior nevirapine exposure through regimens used for prevention of mother-to-child transmission (PMTCT) [6, 7] . The preference for protease inhibitor based initial ART in this age group is unique, as NNRTI-based therapy is recommended by WHO as first-line for all other populations, including older children (3 years old). However, liquid lopinavir/r presents major logistic barriers to widespread use, including high cost, coldchain requirement and poor palatability. As a result, the WHO recommendations advise initiation of a nevirapine-based ART regimen for this age group if lopinavir/r is not available or feasible, as deferring ART completely would be expected to carry a higher risk of morbidity and mortality in this age group than initiating therapy with a regimen that has a somewhat higher risk of virologic failure. As these guidelines were being finalized, efavirenz was licensed for infants and young children (3 months old), but further evaluation will be required in order to determine whether this drug will assume a role in initial therapy of children less than 3 years old in the future, as there remain concerns regarding the pharmacokinetics and appropriate dosing of efavirenz in young children [8] . Studies underway to evaluate raltegravir and other drugs in infants and young children offer hope for new and improved options for initial therapy in the future.
The WHO recommendations include another strategy to address the difficulties of continued use of lopinavir/ r-based ART in young children. On the basis of the results of the NEVEREST study [9] , the WHO guidelines provide an option for substituting an NNRTI for lopinavir/r in those infants and young children who have achieved sustained virologic suppression (plasma viral load <400 copies/ml). This strategy may also preserve protease inhibitor activity for patients who develop treatment failure and NNRTI drug resistance later. This approach depends upon the availability of virologic monitoring, which may limit the extent of its use.
Tuberculosis remains a major problem for children with HIV infection, and interactions between antituberculosis and antiretroviral drugs are an even greater problem for young children who cannot use efavirenz. On the basis of results of the ARROW trial that demonstrated high efficacy of triple NRTI therapy (zidovudine þ abacavir þ lamivudine) in maintaining virologic suppression in children who achieved virologic suppression on a full NNRTI-based ART regimen [10] , there is a new recommendation to use this triple NRTI S134
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Recommendation

Strength of recommendation/quality of evidence
A lopinavir/ritonavir (lopinavir/r)-based regimen should be used as first-line ART for all HIV-infected children younger than 3 years (36 months) of age, regardless of NNRTI exposure. If lopinavir/r is not feasible, treatment should be initiated with an nevirapine-based regimen
Strong recommendation, moderate-quality evidence
Where viral load monitoring is available, consideration can be given to substituting lopinavir/r with an NNRTI after virological suppression is sustained
Conditional recommendation, low-quality evidence
In HIV-infected infants and children younger than 3 years of age, abacavir þ lamivudine þ zidovudine is recommended as an option for children who develop tuberculosis while on an ART regimen containing nevirapine or lopinavir/r. Once tuberculosis therapy has been completed, this regimen should be stopped and the original regimen should be restarted
Strong recommendation, moderate-quality evidence
For HIV-infected infants and children younger than 3 years of age, the NRTI backbone for an ART regimen should be abacavir or zidovudine þ lamivudine
Strong recommendation, low-quality evidence
For HIV-infected infants and children 3 years and older (including adolescents), efavirenz is the preferred NNRTI for first-line treatment and nevirapine is the alternative
For adolescents infected with HIV (10 to 19 years old) weighing 35 kg or more, the NRTI backbone for an ART regimen should align with that of adults and be one of the following, in preferential order: tenofovir disoproxil fumarate þ lamivudine (or emtricitabine); zidovudine þ lamivudine; abacavir þ lamivudine Strong recommendation, low-quality evidence CD4 þ T-cell count 350 cells/mlstrong recommendation, moderate quality of evidence CD4 þ T-cell count between 350 and 500 cells/mlconditional recommendation, very low quality of evidence strategy temporarily for the duration of tuberculosis therapy and then resume the original, standard ART regimen once tuberculosis therapy has been completed. Other options include optimizing the nevirapine dose, substituting nevirapine for lopinavir/r or super-boosting lopinavir/r with additional ritonavir. All of these approaches have drawbacks, however, and evaluation of efavirenz and other drug options (e.g. raltegravir) in children less than 3 years old who are receiving tuberculosis therapy are warranted. For children more than 3 years old who develop tuberculosis while on an ART regimen, no change is required for those already receiving efavirenz-based regimens and changing nevirapine or lopinavir/r to efavirenz is a recommended option, provided there is no history of NNRTI treatment failure.
The choice of preferred NRTI backbone for children is limited by those drugs that are available in appropriate formulations and that have data available for at least safety and pharmacokinetics to allow appropriate dosing, and ideally for efficacy as well. Although there is a stated preference for abacavir over zidovudine based on the general principle of using nonthymidine analogues (such as abacavir) in first-line regimens and thymidine analogues (such as zidovudine) in second-line regimens, both of these drugs, together with lamivudine, are firstline recommended NRTI backbones for children under age 3 years. Tenofovir disoproxil fumarate is part of WHO-recommended first-line regimens for adolescents, pregnant women and nonpregnant adults and is included in NRTI options for first-line ART regimens in children ages 3 to more than 10 years, but there are no safety or pharmacokinetic data for use of tenofovir disoproxil fumarate in children under age 2 years and very limited information about its use in children 2-3 years old, though it is licensed for children at least 2 years old. A dual NRTI backbone of tenofovir disoproxil fumarate in combination with lamivudine (or emtricitabine) is generally recommended for people with hepatitis B (HBV)-HIV coinfection, but for young children with HBV coinfection, the optimal ART regimen is not known. Although d4T has been strongly discouraged for first-line regimen options for adolescents and adults based on toxicity concerns, it remains an option in first-line ART for children less than 3 years old in special circumstances. The currently limited availability of abacavir, inability to use zidovudine in children with severe anaemia and lack of other NRTI options mean that these special circumstances are relatively common.
Recommended second-line ART regimens are also constrained by limited drug options available for children under age 3 years. Because resistance is almost uniform when NNRTI-based regimens fail, lopinavir/r replaces nevirapine or efavirenz in cases of ART failure. For most children less than 3 years old who fail first-line lopinavir/ r-based ART, however, the WHO no longer recommends a change in therapy, because protease inhibitor resistance takes much longer to accumulate, nevirapine has relatively poor performance in this age group and no other options currently exist.
The 2013 WHO guidelines affirm that ART interruption is not recommended for children in this age group. The guidelines also include a new section outlining considerations for simplifying and harmonizing ART regimens in children who have no prior history or current evidence of treatment failure. A transition to simpler and better tolerated regimens as children grow older and new drug options become available will be increasingly commonplace in many programmes.
